

CANTOR COLBURN LLP
INTELLECTUAL PROPERTY ATTORNEYS
55 Griffin Road South
Bloomfield, CT 06002

RECEIVED
CENTRAL FAX CENTER
SEP 30 2004

Tel: (860) 286-2929
Fax: (860) 286-0115

FACSIMILE TRANSMITTAL SHEET

DATE: September 30, 2004

TO: USPTO IDS Division

cc:

FAX NO.: (703) 872-3306

FROM: Karen A. LeClair

TOTAL NUMBER OF PAGES SENT
(INCLUDING THIS COVER SHEET): (14) including this cover sheet


COMMENTS: RE:CSO-0001-P

If there are any problems with this facsimile transmission, please contact Leila Leahy
at: (860) 286-2929, Ext. 1187. Thank you.

IMPORTANT: This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that reading, disseminating, distributing or copying this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. CSO-0001-P
In Re Application Of: CHEN					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/647,458	August 1, 2003	NYA	23413	1614	2036
Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

Docket No.
CSO-0001-P

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						
In Re Application: CHEN						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/647,458	August 1, 2003	NYA	23413	1614	2036	
Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE						
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
<input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below. <ul style="list-style-type: none"> <input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required. 						
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
Certificate of Transmission by Facsimile* <div style="border: 1px solid black; padding: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. (703) 872-9306 </div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> 9/30/04 (Date)  Letta Leahy Signature Typed or Printed Name of Person Signing Certificate </div> <div style="width: 45%;"> _____ (Date)  Karen A. LeCuyer Signature Typed or Printed Name of Person Signing Certificate </div> </div> <p>*This certificate may only be used if paying by deposit account.</p>						
Certificate of Mailing by First Class Mail <div style="border: 1px solid black; padding: 5px;"> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450". _____ (Date) Signature of Person Mailing Correspondence Typed or Printed Name of Person Mailing Certificate </div>						
Dated: September 30, 2004						
CO:						

CSO-0001-P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sophie Chen)
Serial No.: 10/647,458)
Filing Date: August 1, 2003)
For: BOTANICAL EXTRACT)
COMPOSITIONS AND METHODS)
OF USE)

Group Art Unit: 1614
Examiner: NYA

RECEIVED
CENTRAL FAX CENTER
SEP 30 2004

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By:

Karen A. LeCuyer
Karen A. LeCuyer Ph.D.
Registration No. 51,928

Date: September 30, 2004
Customer No. 23,413
(860) 286-2929

185 copy.

From the INTERNATIONAL SEARCHING AUTHORITY

To:
 CANTOR COLBURN LLP
 Attn: Reimer, Leah M.
 55 Griffin Road South
 Bloomfield, CT 06002
 UNITED STATES OF AMERICA

JUL 06 2004
PCT
CANTOR COLBURN LLP

NOTIFICATION OF TRANSMITTAL OF
 THE INTERNATIONAL SEARCH REPORT
 OR THE DECLARATION

(PCT Rule 44.1)

		Date of mailing (day/month/year)	01/07/2004
Applicant's or agent's file reference CSO-0001PF - PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below		
International application No. PCT/US 03/24088	International filing date (day/month/year)		
Applicant CHEN, Sophie	01/08/2003		

1. The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.
 Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 48):

When? The time limit for filing such amendments is normally 18 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 760.14.85

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
 the protest together with the decision thereon has been transmitted to the International Bureau together with the applicants request to forward the texts of both the protest and the decision thereon to the designated Offices.
 no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Further action(s): The applicant is reminded of the following:

Shortly after 18 months from the priority date, the International application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of all technical preparations for International publication.

Within 19 months from the priority date, a demand for International preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority European Patent Office, P.B. 8618 Patenten 2 NL-2200 RD The Hague Tel. (+31-70) 340-2040, Tx. 31 651 esp nl, Fax: (+31-70) 340-3016	Authorized officer Sandrine Polenzani
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------

Form PCT/ISA/220 (July 1998)

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the International search report, one opportunity to amend the claims of the International application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the International Preliminary Examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before International publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the International phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the International application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the International search report or 18 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for International publication (Rule 44.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 16.2).

Where a demand for International Preliminary Examination has already been filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the International application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b));

The amendments must be submitted with a letter.

The letter will not be published with the International application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the International application is English, the letter must be in English; if the language of the International application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 30, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 16 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 8 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added; or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46(4))

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments into the procedure before that Authority (see Rules 80.2(a) and 82.2, first sentence). For further information, see the Notes to the demand form (PCT/PEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Office, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference C80-00011FF - PCT	FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, Item 5 below.	
International application No. PCT/US 03/24088	International filing date (day/month/year) 01/08/2003	(Earliest) Priority Date (day/month/year) 06/03/2002
Applicant CHEN, Sophie		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of **07** sheets.
 It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 29.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. Certain claims were found unsearchable (See Box I).

3. Unity of Invention is lacking (See Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

**BOTANICAL EXTRACT COMPOSITIONS WITH ANTI-CANCER OR PHYTOESTROGENIC ACTIVITY
COMPRISING PRENYL FLAVONOIDS**

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.4(b), by this Authority as it appears in Box II. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

1

None of the figures.

BOX I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
- Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

- As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
- As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
- As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
- No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 (part), 2, 3-7 (part), 8, 9-11 (part)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

International Application No. PCT/ US 03/24088

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 218

Continuation of Box I.1

Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: -

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: -

The formula given in claim 1 is not clear. Therefore the search has been carried out for a prenyl flavonoid represented by the formula in claim 1 with the proviso that at least one of R31 and R30 (instead of R33) is 3-methyl-2-but enyl. R33 can't be isoprenyl since an alkenyl substituent is not allowed for R33 (see the formulae in claims 1 and 7).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline E-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

International Application No. PCT/ US 03/24088

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (part.), 2, 3-7 (part.), 8, 9-11 (part.)

Compositions comprising an anti-cancer agent and a prenyl
flavonoid and their use for the treatment of cancer

2. claims: 1 (part.), 3-7 (part.), 9-11 (part.)

Compositions comprising an anti-cancer agent and
formononetin and their use for the treatment of cancer

According to International Patent Classification (IPC) or to both national classification and IPC

FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, SCISEARCH, PASCAL, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 159 963 A (PROTEIN TECH INT) 5 December 2001 (2001-12-05) page 9, lines 37-46; claims	1,7
Y	JANG, DAE SIK ET AL: "Prenylated flavonoids of the leaves of Macaranga conifera with inhibitory activity against cyclooxygenase-2" PHYTOCHEMISTRY (ELSEVIER) (2002), 61(7), 867-872, XP002269642 * compounds 3,4,5 * abstract	1-11
Y		1-11

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.*** Special categories of cited documents:**"A" document defining the general state of the art which is not
concerned to be of particular relevance

"B" earlier document

"C" document which may throw doubts on priority (claims) or
which is cited to establish the publication date of another
citation or other special reason (as specified)"D" document referring to an oral disclosure, use, exhibition or
other means of publication"P" document published prior to the International filing date but
later than the priority date claimed"T" later document published after the International filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention"X" document of particular relevance; the claimed invention
cannot be considered as novel or cannot be considered to
involve an inventive step when the document is taken alone"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"Z" document member of the same patent family

Date of the actual completion of the International search

10 February 2004

Date of mailing of the International search report

01.07.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5516 Patentlan 2
NL - 2280 Rijswijk
Tel: (+31-70) 340-3016
Fax: (+31-70) 340-3016

Authorized officer

Friederich, M

2

Form PCT/ISA/810 (second sheet) (January 2004)

page 1 of 2

		RELEVANT TO CLAIM NO.
Y	FUKAI, TOSHIRO ET AL: "Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines" ANTI-CANCER RESEARCH (2000), 20(4), 2525-2536, XP001016407 table 1	1-11
Y	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 03, 23 February 1998 (1998-02-27) & JP 09 301915 A (SANKYO CO LTD), 25 November 1997 (1997-11-25) abstract	1-11
2		

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

page 2 of 2

EP 1159963	A	05-12-2001	EP	1159963 A1	05-12-2001
JP 09301915	A	25-11-1997	NONE		

No proper IDS form submitted

/Chris Simmons/

06/04/2009

Form PCT/ISA/210 (Joint family annex) (January 2004)